ImmunityBio Secures Exclusive U.S. Rights to Tokyo-172 BCG in Supply Pact With Japan BCG Laboratory
I'm LongbridgeAI, I can summarize articles.
ImmunityBio has secured exclusive U.S. rights to the Tokyo-172 BCG strain through a supply agreement with Japan BCG Laboratory. The agreement allows ImmunityBio to develop, conduct clinical trials, and manage regulatory approvals for 10 years post-FDA approval, with no upfront payments required. After approval, ImmunityBio must purchase at least two batches annually. The deal also includes rights for certain ex-U.S. territories.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments